Identification of new biomarkers of low-dose GH replacement therapy in GH-deficient patients

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 7, 2011, Pages 2089-2097

  Cruz Topete, Diana ^a   Jorgensen, Jens Otto L ^c   Christensen, Britt ^c   Sackmann Sala, Lucila ^a   Krusenstjerna Hafstrøm, Thomas ^c   Jara, Adam ^a,b   Okada, Shigeru ^a,b   Kopchick, John J ^a,b  

^a OHIO UNIVERSITY   (United States)

^b Department of Chemistry and Biochemistry   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; GROWTH HORMONE; HAPTOGLOBIN; LIOTHYRONINE; SOMATOMEDIN C; THYROXINE;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; INSULIN LIKE GROWTH FACTOR 1 BLOOD LEVEL; LEAN BODY WEIGHT; LIOTHYRONINE BLOOD LEVEL; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; NONFUNCTIONING PITUITARY ADENOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; THYROXINE BLOOD LEVEL; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOMA; ADULT; BIOLOGICAL MARKERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MASS SPECTROMETRY; PITUITARY NEOPLASMS; TREATMENT OUTCOME;

EID: 79960109379     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0197     Document Type: Article

References (38)

1. Corneli G, Baldelli R, Di Somma C, Rovere S, Gaia D, Pellegrino M, Gasco V, Durante C, Grottoli S, Colao A, Tamburrano G, Lombardi G, Ghigo E, Aimaretti G 2003 Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. Growth Horm IGF Res 13:104-108 (Pubitemid 36701656)
2. Comtois R, Beauregard H, Somma M,Serri O, Aris-Jilwan N, Hardy J 1991 The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68:860-866
3. Bates AS, Van't Hoff W, Jones PJ, Clayton RN 1996 The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81:1169-1172
4. Cuneo RC, Salomon F, McGauley GA, Sonksen PH 1992 The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 37:387-397
5. Jorgensen JO, Vahl N, Hansen TB, Thuesen L, Hagen C, Christiansen JS 1996 Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol (Oxf) 45:681-688 (Pubitemid 27032313)
6. Jørgensen JO, Thuesen L, Müller J, Ovesen P, Skakkebaek NE, Christiansen JS 1994 Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 130:224-228 (Pubitemid 24117900)
7. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P 2004 Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89:2192-2199 (Pubitemid 38619852)
8. Rosenfalck AM, Maghsoudi S, Fisker S, Jørgensen JO, Christiansen JS, Hilsted J, Vølund AA, Madsbad S 2000 The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 85:4173-4181 (Pubitemid 32063027)
9. Ho KK 2007 Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695-700
10. Chung L, Clifford D, Buckley M, Baxter RC 2006 Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J Clin Endocrinol Metab 91:671-677 (Pubitemid 43236942)
11. Christensen B, Sackmann-Sala L, Cruz-Topete D, Jørgensen JO, Jessen N, Lundby C, Kopchick JJ 2011 Novel serum biomarkers for erythropoietin use in humans: a proteomic approach. J Appl Physiol 110:149-156
12. Cruz-Topete D, Christensen B, Sackmann-Sala L, Okada S, Jorgensen JO, Kopchick JJ 2011 Serum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity. Eur J Endocrinol 164:157-167
13. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ 2009 Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 19:471-477
14. Chatterjee SK, Zetter BR 2005 Cancer biomarkers: knowing the present and predicting the future. Future Oncol 1:37-50
15. Mauri P, Scigelova M 2009 Multidimensional protein identification technology for clinical proteomic analysis. Clin Chem Lab Med 47:636-646
16. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
17. Frystyk J, Dinesen B, Orskov H 1995 Non-competitive time-resolved immunofluorometric assays for determination of human insulin- like growth factor I and II. Growth Regul 5:169-176 (Pubitemid 26018330)
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
19. List EO, Berryman DE, Palmer AJ, Qiu L, Sankaran S, Kohn DT, Kelder B, Okada S, Kopchick JJ 2007 Analysis of mouse skin reveals proteins that are altered in a diet-induced diabetic state: a new method for detection of type 2 diabetes. Proteomics 7:1140-1149 (Pubitemid 46649163)
20. Qiu L, List EO, Kopchick JJ 2005 Differentially expressed proteins in the pancreas of diet-induced diabetic mice. Mol Cell Proteomics 4:1311-1318 (Pubitemid 41448718)
21. Ding J, List EO, Okada S, Kopchick JJ 2009 Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm IGF Res 19:399-407
22. Dabkowski ER, Baseler WA, Williamson CL, Powell M, Razunguzwa TT, Frisbee JC, Hollander JM 2010 Mitochondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes. Am J Physiol Heart Circ Physiol 299:H529-H540
23. Sheskin D 1997 Handbook of parametric and nonparametric statistical procedures. Boca Raton, FL: CRC Press
24. Hansen TB, Brixen K, Vahl N, Jorgensen JO, Christiansen JS, Mosekilde L, Hagen C 1996 Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 81:3352-3359 (Pubitemid 26296215)
25. Misra M, Miller KK, Bjornson J, Hackman A, Aggarwal A, Chung J, Ott M, Herzog DB, Johnson ML, Klibanski A 2003 Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab 88:5615-5623 (Pubitemid 38033024)
26. Fazeli PK, Lawson EA, Prabhakaran R, Miller KK, Donoho DA, Clemmons DR, Herzog DB, Misra M, Klibanski A 2010 Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 95:4889-4897
27. Campbell RM, Scanes CG 1988 Inhibition of growth hormonestimulated lipolysis by somatostatin, insulin, and insulin-like growth factors (somatomedins) in vitro. Proc Soc Exp Biol Med 189:362-366 (Pubitemid 19023665)
28. Simpson HL, Jackson NC, Shojaee-Moradie F, Jones RH, Russell-Jones DL, Sönksen PH, Dunger DB, Umpleby AM 2004 Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 89:425-432 (Pubitemid 38185880)
29. Jörgensen JO, Pedersen SA, Thuesen L, Jörgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1:1221-1225 (Pubitemid 19140325)
30. Jørgensen JO, Pedersen SA, Laurberg P, Weeke J, Skakkebaek NE, Christiansen JS 1989 Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism. J Clin Endocrinol Metab 69:1127-1132 (Pubitemid 20010037)
31. Zhang Q, Wang J, Dong R, Yang S, Zheng S 2011 Identification of novel serum biomarkers in child nephroblastoma using proteomics technology. Mol Biol Rep 38:631-638
32. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schömig A, Kastrati A 2002 Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 48:1377-1382 (Pubitemid 34925770)
33. Van Vlierberghe H, Langlois M, Delanghe J 2004 Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 345:35-42 (Pubitemid 38749169)
34. Yildiz M, Arslanoglu I, Yildiz N, Nartop F, Isik K, Isguven P 2000 Effects of growth hormone replacement therapy on lipids, lipoproteins and apolipoproteins: is the increased apolipoprotein A-1/B ratio the only benefit? Pediatr Int 42:151-154
35. Lanes R, Soros A, Gunczler P, Paoli M, Carrillo E, Villaroel O, Palacios A 2006 Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. J Pediatr 149:324-329 (Pubitemid 44308432)
36. Schaefer GB, Greger NG, Fesmire JD, Blackett PR, Wilson DP, Frindik JP 1994 Lipids and apolipoproteins in growth hormone-deficient children during treatment. Metabolism 43:1457-1461 (Pubitemid 24382693)
37. Blackett PR, Weech PK, McConathy WJ, Fesmire JD 1982 Growth hormone in the regulation of hyperlipidemia. Metabolism 31:117-1120
38. Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG, Goulis DG, Makedou A, Makris P, Slavakis A, Avramides AI 2008 Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf) 69:279-284 (Pubitemid 352009020)